Corcept Beginning Mifepristone Pivotal Trials For Psychotic Depression
This article was originally published in The Pink Sheet Daily
Executive Summary
The first of two trials testing rapid and sustained relief of psychotic features, designed under special protocol assessment with FDA, will begin "immediately," Corcept says. Corlux is expected to share the same safety restrictions as Mifeprex (RU-486).